Details for Patent: 8,138,199
✉ Email this page to a colleague
Which drugs does patent 8,138,199 protect, and when does it expire?
Patent 8,138,199 protects INREBIC and is included in one NDA.
This patent has fifty-one patent family members in twenty-seven countries.
Summary for Patent: 8,138,199
| Title: | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| Abstract: | The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases. |
| Inventor(s): | Glenn Noronha, John D. Hood, Richard M. Soll |
| Assignee: | Impact Therapeutics Inc , Impact Biomedicines Inc |
| Application Number: | US12/253,374 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 8,138,199
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | 8,138,199 | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,138,199
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1951684 | ⤷ Start Trial | 301104 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1951684 | ⤷ Start Trial | 122021000023 | Germany | ⤷ Start Trial |
| European Patent Office | 1951684 | ⤷ Start Trial | LUC00204 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1951684 | ⤷ Start Trial | PA2021509 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1951684 | ⤷ Start Trial | 2021C/513 | Belgium | ⤷ Start Trial |
| European Patent Office | 1951684 | ⤷ Start Trial | 14/2021 | Austria | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
